Publications | PubMed=2519219 Ohtsuki T., Yawata Y., Namba M. Establishment and characterization of five human myeloma cell lines. Hum. Cell 2:297-303(1989) PubMed=2768132; DOI=10.1007/BF02623725 Namba M., Ohtsuki T., Mori M., Togawa A., Wada H., Sugihara T., Yawata Y., Kimoto T. Establishment of five human myeloma cell lines. In Vitro Cell. Dev. Biol. 25:723-729(1989) PubMed=8943038; DOI=10.1073/pnas.93.24.13931 Bergsagel P.L., Chesi M., Nardini E., Brents L.A., Kirby S.L., Kuehl W.M. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc. Natl. Acad. Sci. U.S.A. 93:13931-13936(1996) PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T. Screening the p53 status of human cell lines using a yeast functional assay. Mol. Carcinog. 19:243-253(1997) DOI=10.1002/1438-826X(200005)1:1<48::AID-GNFD48>3.0.CO;2-B Otsuki T., Yamada O., Yata K., Nakazawa N., Taniwaki M., Sakaguchi H., Yawata Y., Ueki A. Genetic and biological characterization of human myeloma cell lines: an overview of the lines established at Kawasaki Medical School. Gene Funct. Dis. 1:48-56(2000) DOI=10.1007/0-306-46877-8_4 Jernberg-Wiklund H., Nilsson K. Multiple myeloma cell lines. (In) Human cell culture. Vol. 3. Cancer Cell Lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York (2000) PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2 Drexler H.G., Matsuo Y. Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia. Leuk. Res. 24:681-703(2000) DOI=10.1016/B978-0-12-221970-2.50457-5 Drexler H.G. The leukemia-lymphoma cell line factsbook. (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001) PubMed=11157491; DOI=10.1182/blood.V97.3.729 Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A., Kuehl W.M., Bergsagel P.L. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 97:729-736(2001) PubMed=15215163; DOI=10.1016/S0002-9440(10)63276-2 Inoue J., Otsuki T., Hirasawa A., Imoto I., Matsuo Y., Shimizu S., Taniwaki M., Inazawa J. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. Am. J. Pathol. 165:71-81(2004) PubMed=17171682; DOI=10.1002/gcc.20404 Lombardi L., Poretti G., Mattioli M., Fabris S., Agnelli L., Bicciato S., Kwee I., Rinaldi A., Ronchetti D., Verdelli D., Lambertenghi-Deliliers G., Bertoni F., Neri A. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. Genes Chromosomes Cancer 46:226-238(2007) PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003 Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J., Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T., Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C., Brents L.A., Kumar S.K., Greipp P., Dispenzieri A., Bryant B., Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M., Stewart A.K., Carpten J.D., Bergsagel P.L. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12:131-144(2007) PubMed=18647998; DOI=10.1093/jncimonographs/lgn011 Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M. Characterization of MYC translocations in multiple myeloma cell lines. J. Natl. Cancer Inst. Monogr. 39:25-31(2008) PubMed=18700954; DOI=10.1186/1755-8794-1-37 Ronchetti D., Lionetti M., Mosca L., Agnelli L., Andronache A., Fabris S., Lambertenghi-Deliliers G., Neri A. An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Med. Genomics 1:37.1-37.9(2008) PubMed=21173094; DOI=10.3324/haematol.2010.033456 Moreaux J., Klein B., Bataille R., Descamps G., Maiga S., Hose D., Goldschmidt H., Jauch A., Reme T., Jourdan M., Amiot M., Pellat-Deceunynck C. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 96:574-582(2011) PubMed=22460905; DOI=10.1038/nature11003 Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607(2012) PubMed=23992230; DOI=10.1111/ejh.12192 Greenberg A.J., Walters D.K., Kumar S.K., Rajkumar S.V., Jelinek D.F. Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels. Eur. J. Haematol. 91:504-513(2013) PubMed=25485619; DOI=10.1038/nbt.3080 Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 33:306-312(2015) PubMed=25688540; DOI=10.1002/cyto.a.22643 Maiga S., Brosseau C., Descamps G., Dousset C., Gomez-Bougie P., Chiron D., Menoret E., Kervoelen C., Vie H., Cesbron A., Moreau-Aubry A., Amiot M., Pellat-Deceunynck C. A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines. Cytometry A 87:285-288(2015) PubMed=25877200; DOI=10.1038/nature14397 Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M. A resource for cell line authentication, annotation and quality control. Nature 520:307-311(2015) PubMed=26589293; DOI=10.1186/s13073-015-0240-5 Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C. TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. Genome Med. 7:118.1-118.7(2015) PubMed=30285677; DOI=10.1186/s12885-018-4840-5 Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P. Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines. BMC Cancer 18:940.1-940.13(2018) PubMed=30545397; DOI=10.1186/s13045-018-0679-0 Tessoulin B., Moreau-Aubry A., Descamps G., Gomez-Bougie P., Maiga S., Gaignard A., Chiron D., Menoret E., Le Gouill S., Moreau P., Amiot M., Pellat-Deceunynck C. Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways. J. Hematol. Oncol. 11:137.1-137.13(2018) PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019) PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019) PubMed=32123307; DOI=10.1038/s41375-020-0785-1 Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B., Sirota M., Wiita A.P. Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis. Leukemia 34:2754-2765(2020) |